[en] We examined the effect of pioglitazone, a peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist of the thiazolidinedione class, on dopaminergic nerve cell death and glial activation in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. The acute intoxication of C57BL/6 mice with MPTP led to nigrostriatal injury, as determined by tyrosine hydroxylase (TH) immunocytochemistry, and HPLC detection of striatal dopamine and metabolites. Damage to the nigrostriatal dopamine system was accompanied by a transient activation of microglia, as determined by macrophage antigen-1 (Mac-1) and inducible nitric oxide synthase (iNOS) immunoreactivity, and a prolonged astrocytic response. Orally administered pioglitazone (approximately 20 mg/kg/day) attenuated the MPTP-induced glial activation and prevented the dopaminergic cell loss in the substantia nigra pars compacta (SNpc). In contrast, there was little reduction of MPTP-induced dopamine depletion, with no detectable effect on loss of TH immunoreactivity and glial response in the striatum of pioglitazone-treated animals. Low levels of PPARgamma expression were detected in the ventral mesencephalon and striatum, and were unaffected by MPTP or pioglitazone treatment. Since pioglitazone affects primarily the SNpc in our model, different PPARgamma-independent mechanisms may regulate glial activation in the dopaminergic terminals compared with the dopaminergic cell bodies after acute MPTP intoxication.
Disciplines :
Neurology
Author, co-author :
Breidert, T; INSERM U289, Experimental Neurology and Therapeutics, Hôpital de la Pitié-Salpêtrière, Paris, France. breidert@ccr.jussieu.fr
Callebert, J; Service de Biochimie et Biologie Moléculaire, Hôpital de Lariboisière, Paris, France
HENEKA, Michael ; Department of Neurology, University of Bonn, Bonn, Germany
Landreth, G; Department of Neurosciences and Neurology, Case Western Reserve University, School of Medicine, Cleveland, OH, United States
Launay, J M; Service de Biochimie et Biologie Moléculaire, Hôpital de Lariboisière, Paris, France
Hirsch, E C; INSERM U289, Experimental Neurology and Therapeutics, Hôpital de la Pitié-Salpêtrière, Paris, France
External co-authors :
yes
Language :
English
Title :
Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease.
Akiyama H., McGeer P.L. (1989) Microglial response to 6-hydroxydopamine-induced substantia nigra lesions. Brain Res. 489:247-253.
Bal-Price A., Brown G.C. (2001) Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity. J. Neurosci. 21:6480-6491.
Bernardo A., Levi G., Minghetti L. (2000) Role of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) and its natural ligand 15-deoxy-delta12,14-prostaglandin J2 in the regulation of microglial functions. Eur. J. Neurosci. 12:2215-2223.
Boka G., Anglade P., Wallach D., Javoy-Agid F., Agid Y., Hirsch E.C. (1994) Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci. Lett. 172:151-154.
Chao C.C., Hu S., Molitor T.W., Shaskan E.G., Peterson P.K. (1992) Activated microglia mediate neuronal cell injury via a nitric oxide mechanism. J. Immunol. 149:2736-2741.
Combs C.K., Johnson D.E., Karlo J.C., Cannady S.B., Landreth G.E. (2000) Inflammatory mechanisms in Alzheimer's disease: Inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci. 20:558-567.
Cullingford T.E., Bhakoo K., Peuchen S., Dolphin C.T., Patel R., Clark J.B. (1998) Distribution of mRNAs encoding the peroxisome proliferator-activated receptor alpha, beta, and gamma and the retinoid X receptor alpha, beta, and gamma in rat central nervous system. J. Neurochem. 70:1366-1375.
Dehmer T., Lindenau J., Haid S., Dichgans J., Schulz J.B. (2000) Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J. Neurochem. 74:2213-2216.
Delerive P., Fruchart J.C., Staels B. (2001) Peroxisome proliferatoractivated receptors in inflammation control. J. Endocrinol. 169:453-459.
Feinstein D.L., Brosnan C.F., Sharp A., Landreth G.E., Gavrilyuk V., Wullner U., Heneka M.T. (2001) Suppression of experimental autoimmune encephalomyelitis by pioglitazone, a PPAR-gamma agonist. Soc. Neurosci. Abstracts 27:10215.
Franklin K.B.J., Paxinos G. The Mouse Brain in Stereotaxic Coordinates, Academic Press, Sydney; 1996.
Ghulam N., Sager T., Laursen H., Vaudano E. (2001) Minocycline reduces microglia activation in the chronic MPTP mouse model of Parkinson's disease. Soc. Neurosci. Abstracts 27:8878.
He B.P., Tay S.S., Leong S.K. (1997) Microglia responses in the CNS following sciatic nerve transection in C57BL/WId(s) and BALB/c mice. Exp. Neurol. 146:587-595.
He Y., Appel S., Le W. (2001) Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res. 909:187-193.
Heneka M.T., Klockgether T., Feinstein D.L. (2000) Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J. Neurosci. 20:6862-6867.
Hirsch E.C. (2000) Glial cells and Parkinson's disease. J. Neurol. 247.
Hirsch E., Graybiel A.M., Agid Y.A. (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334:345-348.
Hunot S., Boissière F., Faucheux B., Brugg B., Mouatt-Prigent A., Agid Y., Hirsch E.C. (1996) Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 72:355-363.
Hunot S., Brugg B., Ricard D., Michel P.P., Muriel M.P., Ruberg M., Faucheux B.A., Agid Y., Hirsch E.C. (1997) Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with Parkinson disease. Proc. Natl. Acad. Sci. USA 94:7531-7536.
Jackson-Lewis V., Jakowec M., Burke R.E., Przedborski S. (1995) Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 4:257-269.
Jiang C., Ting A.T., Seed B. (1998) PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391:82-86.
El-Kebbi I.M., Roser S., Pollet R.J. (1994) Regulation of glucose transport by pioglitazone in cultured muscle cells. Metabolism 43:953-958.
Kim W.G., Mohney R.P., Wilson B., Jeohn G.H., Liu B., Hong J.S. (2000) Regional difference in susceptibility to lipopolysaccharideinduced neurotoxicity in the rat brain: Role of microglia. J. Neurosci. 20:6309-6316.
Kreutzberg G.W. (1996) Microglia: A sensor for pathological events in the CNS. Trends Neurosci. 19:312-318.
Kurkowska-Jastrzebska I., Wronska A., Kohutnicka M., Czlonkowski A., Czlonkowska A. (1999) The inflammatory reaction following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication in mouse. Exp. Neurol. 156:50-61.
Langston J.W., Forno L.S., Tetrud J., Reeves A.G., Kaplan J.A., Karluk D. (1999) Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann. Neurol. 46:598-605.
Lawson L.J., Perry V.H., Dri P., Gordon S. (1990) Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 39:151-170.
Le W., Rowe D., Xie W., Ortiz I., He Y., Appel S.H. (2001) Microglial activation and dopaminergic cell injury: An in vitro model relevant to Parkinson's disease. J. Neurosci. 21:8447-8455.
Li M., Pascual G., Glass C.K. (2000) Peroxisome proliferatoractivated receptor gamma-dependent repression of the inducible nitric oxide synthase gene. Mol. Cell Biol. 20:4699-4707.
Liberatore G.T., Jackson-Lewis V., Vukosavic S., Mandir A.S., Vila M., McAuliffe W.G., Dawson V.L., Dawson T.M., Przedborski S. (1999) Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat. Med. 5:1403-1409.
Liu B., Jiang J.W., Wilson B.C., Du L., Yang S.N., Wang J.Y., Wu G.C., Cao X.D., Hong J.S. (2000) Systemic infusion of naloxone reduces degeneration of rat substantia nigral dopaminergic neurons induced by intranigral injection of lipopolysaccharide. J. Pharmacol. Exp. Ther. 295:125-132.
Lu X., Bing G., Hagg T. (2000) Naloxone prevents microgliainduced degeneration of dopaminergic substantia nigra neurons in adult rats. Neuroscience 97:285-291.
Maeshiba Y., Kiyota Y., Yamashita K., Motohashi M., Tanayama S. (1997) Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. Arzneim-Forschung/Drug Res. 47:29-35.
McGeer P.L., Itagaki S., Boyes B.E., McGeer E.G. (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38:1285-1291.
Mogi M., Harada M., Kondo T., Riederer P., Inagaki H., Minami M., Nagatsu T. (1994) Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci. Lett. 180:147-150.
Palacios J.M., Wiederhold K.H. (1984) Acute administration of 1-N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a compound producing parkinsonism in humans, stimulates [2-14C] deoxyglucose uptake in the regions of the catecholaminergic cell bodies in the rat and guinea pig brains. Brain Res. 301:187-191.
Palombo E., Porrino L.J., Bankiewicz K.S., Crane A.M., Kopin I.J., Sokoloff L. (1988) Administration of MPTP acutely increases glucose utilization in the substantia nigra of primates. Brain Res. 453:227-234.
Przedborski S., Jackson-Lewis V. (1998) Mechanisms of MPTP toxicity. Mov. Disord. 13:35-38.
Ricote M., Li A.C., Willson T.M., Kelly C.J., Glass C.K. (1998) The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391:79-82.
Smith U. (2001) Pioglitazone: Mechanism of action. Int. J. Clin. Pract. supplement 13-18.
Sokoloff L. (1993) Sites and mechanisms of function-related changes in energy metabolism in the nervous system. Dev. Neurosci. 15:194-206.
Takamura T., Ando H., Nagai Y., Yamashita H., Nohara E., Kobayashi K. (1999) Pioglitazone prevents mice from multiple low-dose streptozotocin-induced insulitis and diabetes. Diabetes Res. Clin. Pract. 44:107-114.
Tang Y., Osawa H., Onuma H., Nishimiya T., Ochi M., Makino H. (1999) Improvement in insulin resistance and the restoration of reduced phosphodiesterase 3B gene expression by pioglitazone in adipose tissue of obese diabetic KKAy mice. Diabetes 48:1830-1835.
Viale G., Gambacorta M., Coggi G., Dell'Orto P., Milani M., Doglioni C. (1991) Glial fibrillary acidic protein immunoreactivity in normal and diseased human breast. Virchows Arch. A Pathol. Anat. Histopathol. 418:339-348.
Vodovotz Y., Bogdan C., Paik J., Xie Q.W., Nathan C. (1993) Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor beta. J. Exp. Med. 178:605-613.
